According to the International Agency for Research on Cancer (IARC), nearly 20 million new cancer cases were reported in 2022, including nonmelanoma skin cancers (NMSCs), along with 9.7 million cancer-related deaths, also including NMSCs. The estimates indicate that approximately one in five individuals develop cancer during their lifetime, while about one in nine men and one in 12 women succumb to it. Vinca alkaloid drugs, derived from the periwinkle plant, are extensively utilized in treating various cancer types such as leukemia, lymphoma, breast, lung, and ovarian cancers. The market for these drugs is experiencing consistent growth, propelled by the rising cancer prevalence and the increasing adoption of vinca alkaloid chemotherapy drugs as a viable treatment option.
